Alumis Inc. Common Stock (ALMS)
Alumis Inc. (ALMS) is a biotechnology company focused on developing innovative therapies and solutions primarily within the healthcare and life sciences sectors. The company emphasizes advancing scientific research and technology to address unmet needs in medical treatments, often concentrating on areas such as antibody engineering and advanced therapeutics.
Company News
Alumis reported mixed Q2 2025 results, with missed revenue expectations and high operating expenses due to the ACELYRIN merger. The company completed patient enrollment in key clinical trials for envudeucitinib and maintains sufficient funding through 2027.
Alumis Inc. has completed its merger with ACELYRIN, Inc. The merger strengthens Alumis' balance sheet and supports the advancement of its late-stage pipeline of targeted therapies for immune-mediated diseases.
Alumis Inc. and ACELYRIN, INC. announced that Alumis' stockholders voted to approve the pending merger between the two companies. The merger is expected to close in the second quarter of 2025, subject to customary closing conditions.